Vice President of Global Regulatory Affairs

Johnson Fistel, PLLP investigates claims on behalf of long-term shareholders of Semtech Corporation (SMTC), Roblox Corporation (RBLX), Quantum Corporation (QMCO), and PROCEPT BioRobotics Corporation (PRCT). SAN DIEGO, Oct. 09, 2026 (GLOBE NEWSWIRE) - Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Semtech Corporation (NASDAQ: SMTC), Roblox Corporation (NYSE: RBLX), Quantum Corporation (NASDAQ: QMCO), and PROCEPT BioRobotics Corporation (NASDAQ: PRCT) against certain of their officers and directors for alleged breaches of fiduciary duty. Shareholders who have continuously held shares since the dates listed below and continue to hold those shares may have standing to seek corporate governance reforms and the return of funds to the company. For a named plaintiff, the firm may also seek a reasonable incentive award, subject to court approval. Representation is on a contingency-fee basis, with no legal fees or expenses payable by participating shareholders. Semtech Corporation (NASDAQ: SMTC) If you have held Semtech shares continuously since at least October 10, 2024, and continue to hold those shares, you may have standing to seek corporate governance reforms at Semtech, including improvements to disclosure practices, product oversight, internal controls, and executive accountability. To learn more, visit https://www.johnsonfistel.com/investigations/semtech-corporation/ or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. There is no cost or obligation. Complaint Allegations A previously filed securities class action complaint alleges that Semtech and certain executives made materially false and misleading statements and/or failed to disclose material adverse facts concerning its CopperEdge products. Specifically, the complaint alleges that the products did not meet the needs of a server rack customer or end users, that certain rack architecture changes were required, and that CopperEdge sales would not ramp up during fiscal 2026 as previously represented. Consequently, sales allegedly would be lower than expected, rendering defendants' positive statements about the Company's business and prospects materially misleading and/or without a reasonable basis. Roblox Corporation (NYSE: RBLX) If you have held Roblox shares continuously since at least October 30, 2025, and continue to hold those shares, you may have standing to seek corporate governance reforms at Roblox, including improvements to user-safety oversight, disclosure practices, internal controls, and executive accountability. To learn more, visit https://www.johnsonfistel.com/investigations/roblox-corp-rblx/or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. There is no cost or obligation. Complaint Allegations A previously filed securities class action complaint alleges that Roblox and certain executives made materially false and misleading statements concerning the Company's commitment to protecting young users and the anticipated business impact of its age-verification rollout. The allegations concern whether defendants adequately disclosed risks to user growth, engagement, and financial performance associated with enhanced age-verification requirements. Subsequent disclosures concerning slowing user growth, friction from the age-check rollout, and reductions to revenue and bookings guidance allegedly revealed the misleading nature of prior statements. Quantum Corporation (NASDAQ: QMCO) If you have held Quantum shares continuously since at least November 14, 2024, and continue to hold those shares, you may have standing to seek corporate governance reforms at Quantum, including improvements to revenue-recognition practices, financial reporting, internal controls, and executive oversight. To learn more, visit https://www.johnsonfistel.com/investigations/quantum-corporation-nasdaq-qmco/ or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. There is no cost or obligation. Complaint Allegations A previously filed securities class action complaint alleges that Quantum and certain defendants made materially false and misleading statements and/or failed to disclose material adverse facts concerning the Company's financial reporting. Specifically, the complaint alleges that Quantum improperly recognized revenue during the fiscal year and would need to restate its previously filed third-quarter financial statements. As a result, defendants' statements concerning the Company's business, operations, and prospects allegedly were materially false and misleading and/or lacked a reasonable basis. PROCEPT BioRobotics Corporation (NASDAQ: PRCT) If you have held PROCEPT BioRobotics shares continuously since at least February 27, 2024, and continue to hold those shares, you may have standing to seek corporate governance reforms at PROCEPT BioRobotics, including improvements to sales practices, customer-inventory monitoring, disclosure controls, and executive oversight. To learn more, visit https://www.johnsonfistel.com/investigations/procept-biorobotics-corporation/ or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. There is no cost or obligation. Complaint Allegations A previously filed securities class action complaint alleges that PROCEPT BioRobotics and certain executives misled investors concerning sales of the Company's single-use handpieces for its Aquablation therapy. Specifically, the complaint alleges that PROCEPT used bulk-order discounts to encourage customers to purchase handpieces beyond their procedural needs, pulling sales forward from future periods and artificially inflating reported unit sales and revenues. The complaint further alleges that excess customer inventories undermined future demand and that subsequent disclosures concerning weaker handpiece sales, excess inventory, and the elimination of bulk-purchase discounts revealed the alleged misconduct. About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investors Rights: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on U.S. exchanges. For more information about the firm and how we may be able to help you recover your losses, please visit https://www.johnsonfistel.com. Achievements: In 2024, Johnson Fistel was ranked in the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. The firm has recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel, marking the eighth time it has been recognized among the top U.S. plaintiffs' securities law firms. Johnson Fistel, PLLP 501 W. Broadway, Suite 800 San Diego, CA 92101 James Baker, Investor Relations, or Frank J. Johnson, Esq. (619) 814-4471 [email protected] or [email protected]

INVESTOR ALERT: Pomerantz law Firm reminds investors with losses on their investment in PROCEPT BioRobotics Corporation of class action lawsuit and upcoming deadlines - PRCT. September 22, 2026 18:23 ET | Source: Pomerantz LLP NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) - Pomerantz LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Procept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until September 22, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Procept securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. On August 6, 2025, Procept announced earnings for its second fiscal quarter of 2025, revealing that Procept had only sold approximately 12,750 handpieces in the United States during the quarter. During Procept's earnings call, Chief Financial Officer Kevin Waters reported that Procept expected to ship approximately 13,350 units in the following quarter, significantly below consensus estimates of more than 13,840 units. Procept's quarterly handpiece sales guidance also implied that Procept would need to grow handpiece sales by approximately 25% year-over-year in the fourth quarter in order to meet Procept's annual unit sales guidance. In addition, then-Chief Executive Officer Reza Zadno revealed that Procept was eliminating the role of Chief Commercial Officer in order to "strengthen" Procept's "commercial execution." On this news, Procept's stock price fell approximately 16% over a two-day trading period. Then, on November 4, 2025, Procept announced earnings results for its third fiscal quarter of 2025, revealing that Procept had only sold 13,225 handpieces during the quarter, which missed Procept's sales guidance issued during the prior quarter. During the corresponding conference call, CFO Waters further revealed that Procept was reducing its annual handpiece sales guidance by 1,000 units, down from 53,000 units to 52,000 units to allow for the "optimization of field inventory." CEO Larry L. Wood further admitted that Procept had not "been managing customer inventory by establishing par levels" and that some customers were "probably carrying too much inventory." On this news, Procept's stock price fell more than 10% over a two-day trading period. Finally, on February 25, 2026, Procept announced earnings results for its fourth fiscal quarter and year ending December 31, 2025. Procept revealed that handpiece sales had materially exceeded procedures in every quarter since the first fiscal quarter of 2023, a differential which had consistently grown over time, ultimately resulting in cumulative excess field inventory of more than 10,000 units. Procept further revealed that quarterly handpiece unit sales in the United States had declined significantly from 13,225 units in the third quarter to 9,400 units, representing a sequential decline of nearly 30%. On this news, Procept's stock price fell more than 18% over a two-day trading period. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.